EP0486526B2
(en)
|
1989-08-07 |
2001-03-07 |
Peptech Limited |
Tumour necrosis factor binding ligands
|
US5959087A
(en)
*
|
1989-08-07 |
1999-09-28 |
Peptide Technology, Ltd. |
Tumour necrosis factor binding ligands
|
US20030225254A1
(en)
*
|
1989-08-07 |
2003-12-04 |
Rathjen Deborah Ann |
Tumour necrosis factor binding ligands
|
US7192584B2
(en)
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
US6270766B1
(en)
|
1992-10-08 |
2001-08-07 |
The Kennedy Institute Of Rheumatology |
Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
|
US6830751B1
(en)
|
1994-03-14 |
2004-12-14 |
Genetics Institute, Llc |
Use of IL-12 antagonists in the treatment of rheumatoid arthritis
|
ZA95960B
(en)
*
|
1994-03-14 |
1995-10-10 |
Genetics Inst |
Use of interleukin-12 antagonists in the treatment of autoimmune diseases
|
US20010055581A1
(en)
|
1994-03-18 |
2001-12-27 |
Lawrence Tamarkin |
Composition and method for delivery of biologically-active factors
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
DE122004000004I1
(de)
*
|
1996-02-09 |
2004-08-12 |
Abott Biotechnology Ltd |
Humane Antikörper welche an Humanen TNFalpha binden.
|
US7129061B1
(en)
*
|
1996-08-07 |
2006-10-31 |
Biogen Idec Ma Inc. |
Tumor necrosis factor related ligand
|
US20040009166A1
(en)
*
|
1997-04-30 |
2004-01-15 |
Filpula David R. |
Single chain antigen-binding polypeptides for polymer conjugation
|
WO1998049198A1
(en)
*
|
1997-04-30 |
1998-11-05 |
Enzon, Inc. |
Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
|
US7229841B2
(en)
|
2001-04-30 |
2007-06-12 |
Cytimmune Sciences, Inc. |
Colloidal metal compositions and methods
|
US6407218B1
(en)
|
1997-11-10 |
2002-06-18 |
Cytimmune Sciences, Inc. |
Method and compositions for enhancing immune response and for the production of in vitro mabs
|
US7067144B2
(en)
*
|
1998-10-20 |
2006-06-27 |
Omeros Corporation |
Compositions and methods for systemic inhibition of cartilage degradation
|
US7553487B2
(en)
|
1998-12-14 |
2009-06-30 |
Genetics Institute, Llc |
Method and compositions for treating asthma
|
EP1141286B1
(en)
|
1998-12-14 |
2006-10-18 |
Genetics Institute, LLC |
Cytokine receptor chain
|
DE60045240D1
(de)
*
|
1999-03-02 |
2010-12-30 |
Centocor Inc |
Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
US20040220103A1
(en)
|
1999-04-19 |
2004-11-04 |
Immunex Corporation |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
AU7912600A
(en)
*
|
1999-10-06 |
2001-05-10 |
Basf Aktiengesellschaft |
Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy
|
KR101111103B1
(ko)
|
2000-02-10 |
2012-02-13 |
아보트 러보러터리즈 |
사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법
|
GB0013810D0
(en)
|
2000-06-06 |
2000-07-26 |
Celltech Chiroscience Ltd |
Biological products
|
CN101525384A
(zh)
|
2000-06-29 |
2009-09-09 |
艾博特公司 |
双特异性抗体及其制备方法和用途
|
UA81743C2
(uk)
*
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US20050196755A1
(en)
*
|
2000-11-17 |
2005-09-08 |
Maurice Zauderer |
In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
|
AU2002231736A1
(en)
|
2000-12-22 |
2002-07-08 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Use of repulsive guidance molecule (rgm) and its modulators
|
US6919183B2
(en)
*
|
2001-01-16 |
2005-07-19 |
Regeneron Pharmaceuticals, Inc. |
Isolating cells expressing secreted proteins
|
US20090137416A1
(en)
|
2001-01-16 |
2009-05-28 |
Regeneron Pharmaceuticals, Inc. |
Isolating Cells Expressing Secreted Proteins
|
CA2440676A1
(en)
|
2001-03-22 |
2002-10-03 |
Abbott Gmbh & Co. Kg |
Transgenic animals expressing antibodies specific for genes of interest and uses thereof
|
US6410955B1
(en)
*
|
2001-04-19 |
2002-06-25 |
Micron Technology, Inc. |
Comb-shaped capacitor for use in integrated circuits
|
CA2385745C
(en)
*
|
2001-06-08 |
2015-02-17 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
AU2002316384A1
(en)
*
|
2001-06-26 |
2003-03-03 |
Photomed Technologies, Inc. |
Multiple wavelength illuminator
|
US7364736B2
(en)
|
2001-06-26 |
2008-04-29 |
Amgen Inc. |
Antibodies to OPGL
|
US20050271663A1
(en)
*
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
TWI327597B
(en)
|
2001-08-01 |
2010-07-21 |
Centocor Inc |
Anti-tnf antibodies, compositions, methods and uses
|
WO2003024384A2
(en)
*
|
2001-09-20 |
2003-03-27 |
Magnum Therapeutics |
Improved methods for treatment with viral vectors
|
US20030065382A1
(en)
*
|
2001-10-02 |
2003-04-03 |
Fischell Robert E. |
Means and method for the treatment of coronary artery obstructions
|
CA2460916A1
(en)
|
2001-10-04 |
2003-04-10 |
Laura Carter |
Methods and compositions for modulating interleukin-21 receptor activity
|
EP1494710A4
(en)
*
|
2002-03-26 |
2007-03-21 |
Centocor Inc |
DIABETES-RELEVANT IMMUNOGLOBULIN-BASED PROTEINS, COMPOSITIONS, PROCESSES AND USES
|
US20030206898A1
(en)
*
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
US20040009172A1
(en)
*
|
2002-04-26 |
2004-01-15 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
CN102764436A
(zh)
|
2002-07-19 |
2012-11-07 |
艾博特生物技术有限公司 |
TNF α相关疾病的治疗
|
US20090280065A1
(en)
*
|
2006-04-10 |
2009-11-12 |
Willian Mary K |
Uses and Compositions for Treatment of Psoriasis
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
WO2004019861A2
(en)
*
|
2002-08-28 |
2004-03-11 |
Pharmacia Corporation |
Stable ph optimized formulation of a modified antibody
|
MY150740A
(en)
*
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
CA2505316C
(en)
|
2002-11-08 |
2014-08-05 |
Ablynx N.V. |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
US20060034845A1
(en)
|
2002-11-08 |
2006-02-16 |
Karen Silence |
Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
|
US20040101939A1
(en)
*
|
2002-11-22 |
2004-05-27 |
Santora Ling C. |
Method for reducing or preventing modification of a polypeptide in solution
|
US20040162414A1
(en)
*
|
2002-11-22 |
2004-08-19 |
Santora Ling C. |
Method for reducing or preventing modification of a polypeptide in solution
|
RU2377253C2
(ru)
*
|
2002-12-02 |
2009-12-27 |
Амген Фремонт,Инк. |
Антитела, специфичные к фактору некроза опухолей, и их применение
|
EP1578782A4
(en)
*
|
2002-12-30 |
2007-09-12 |
Amgen Inc |
COSTIMULATING FACTORIAL THERAPY
|
JP2007525409A
(ja)
*
|
2003-01-08 |
2007-09-06 |
アプライド モレキュラー エボリューション,インコーポレイテッド |
TNF−α結合分子
|
US7101978B2
(en)
*
|
2003-01-08 |
2006-09-05 |
Applied Molecular Evolution |
TNF-α binding molecules
|
CA2512545C
(en)
*
|
2003-01-10 |
2015-06-30 |
Karen Silence |
Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf)
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
RU2005131852A
(ru)
*
|
2003-03-14 |
2006-04-20 |
Уайт (Us) |
Антитела против человеческого рецептора il-21 и их применение
|
EP1460088A1
(en)
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanized anti-CD4 antibody with immunosuppressive properties
|
WO2004098578A2
(en)
*
|
2003-05-12 |
2004-11-18 |
Altana Pharma Ag |
Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
|
FR2856075B1
(fr)
*
|
2003-06-16 |
2007-10-12 |
Monoclonal Antibodies Therapeu |
Procede essentiellement automatise de criblage a grande echelle de cellules secretant des anticorps monoclonaux
|
FR2859725B1
(fr)
*
|
2003-09-16 |
2006-03-10 |
Neovacs |
Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
KR100772800B1
(ko)
*
|
2003-11-17 |
2007-11-01 |
주식회사유한양행 |
인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
|
CA2548179A1
(en)
|
2003-12-02 |
2005-07-21 |
Cytimmune Sciences, Inc. |
Methods and compositions for the production of monoclonal antibodies
|
US7674459B2
(en)
|
2003-12-23 |
2010-03-09 |
Genentech, Inc. |
Treatment of cancer with a novel anti-IL13 monoclonal antibody
|
US7435799B2
(en)
*
|
2004-01-08 |
2008-10-14 |
Applied Molecular Evolution |
TNF-α binding molecules
|
US7625549B2
(en)
|
2004-03-19 |
2009-12-01 |
Amgen Fremont Inc. |
Determining the risk of human anti-human antibodies in transgenic mice
|
EP2418224A3
(en)
|
2004-03-19 |
2013-07-24 |
Amgen Inc. |
Reducing the risk of human and anti-human antibodies through V gene manipulation
|
TWI556829B
(zh)
*
|
2004-04-09 |
2016-11-11 |
艾伯維生物技術有限責任公司 |
用於治療TNFα相關失調症之多重可變劑量療法
|
CN100427504C
(zh)
*
|
2004-06-02 |
2008-10-22 |
北京天广实生物技术有限公司 |
TNFα高亲和力嵌合抗体及其用途
|
US7501121B2
(en)
|
2004-06-17 |
2009-03-10 |
Wyeth |
IL-13 binding agents
|
AR049390A1
(es)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
EP1773394A2
(en)
*
|
2004-08-05 |
2007-04-18 |
Wyeth a Corporation of the State of Delaware |
Antagonizing interleukin-21 receptor activity
|
WO2006041970A2
(en)
*
|
2004-10-08 |
2006-04-20 |
Abbott Biotechnology Ltd. |
Treatment of respiratory syncytial virus (rsv) infection
|
CN101048426A
(zh)
*
|
2004-10-22 |
2007-10-03 |
金克克国际有限公司 |
分离人抗体
|
CN101102792A
(zh)
|
2004-11-19 |
2008-01-09 |
比奥根艾迪克Ma公司 |
治疗多发性硬化
|
CA2930677A1
(en)
|
2005-02-08 |
2006-08-17 |
Genzyme Corporation |
Antibodies to tgfbeta
|
EP1849011A2
(en)
*
|
2005-02-14 |
2007-10-31 |
University of Pittsburgh of the Commonwealth System of Higher Education |
Use of il-17f in diagnosis and therapy of airway inflammation
|
EP1848743A2
(en)
*
|
2005-02-14 |
2007-10-31 |
Wyeth |
Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor
|
WO2006089095A2
(en)
|
2005-02-17 |
2006-08-24 |
Biogen Idec Ma Inc. |
Treating neurological disorders
|
GT200600148A
(es)
*
|
2005-04-14 |
2006-11-22 |
|
Metodos para el tratamiento y la prevencion de fibrosis
|
AU2006244014B2
(en)
*
|
2005-05-10 |
2011-03-17 |
Biogen Ma Inc. |
Treating and evaluating inflammatory disorders
|
AU2012254978C1
(en)
*
|
2005-05-16 |
2017-06-01 |
Abbvie Biotechnology Ltd |
Use of TNF inhibitor for treatment of erosive polyarthritis
|
TWI399384B
(zh)
*
|
2005-05-16 |
2013-06-21 |
Abbott Biotech Ltd |
TNFα抑制劑於治療侵蝕型多發性關節炎之用途
|
WO2006133287A2
(en)
*
|
2005-06-06 |
2006-12-14 |
Wyeth |
Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
|
WO2006131013A2
(en)
|
2005-06-07 |
2006-12-14 |
Esbatech Ag |
STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
|
US20080311078A1
(en)
|
2005-06-14 |
2008-12-18 |
Gokarn Yatin R |
Self-Buffering Protein Formulations
|
US20060286108A1
(en)
*
|
2005-06-16 |
2006-12-21 |
Bell Katherine A |
Topical compositions for the treatment of chronic wounds
|
US20080045949A1
(en)
*
|
2005-06-17 |
2008-02-21 |
Hunt Margaret M |
Method of treating degenerative spinal disorders
|
JP5253159B2
(ja)
*
|
2005-06-24 |
2013-07-31 |
デューク・ユニヴァーシティ |
熱応答性バイオポリマーに基づく直接的ドラッグデリバリーシステム
|
EP2484774A3
(en)
|
2005-07-21 |
2012-11-14 |
Abbott Laboratories |
Multiple gene expression including sorf contructs and methods with polyproteins, pro-proteins, and proteolysis
|
TW200726776A
(en)
*
|
2005-07-29 |
2007-07-16 |
Friedrich Alexander University Of Erlangen Nuremberg |
CD33-specific single-chain immunotoxin and methods of use
|
US20070041905A1
(en)
*
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
US7612181B2
(en)
*
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
EP2500353A3
(en)
|
2005-08-19 |
2012-10-10 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
KR20140053410A
(ko)
|
2005-08-19 |
2014-05-07 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
US8906864B2
(en)
|
2005-09-30 |
2014-12-09 |
AbbVie Deutschland GmbH & Co. KG |
Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
|
WO2007049286A1
(en)
*
|
2005-10-27 |
2007-05-03 |
Tata Memorial Centre |
A system for ex-vivo separation of apoptotic chromatin particles from blood or plasma
|
CN101663048A
(zh)
|
2005-11-01 |
2010-03-03 |
艾博特生物技术有限公司 |
使用生物标志物诊断强直性脊柱炎的方法和组合物
|
AR056806A1
(es)
|
2005-11-14 |
2007-10-24 |
Amgen Inc |
Moleculas quimericas de anticuerpo rankl- pth/ pthrp
|
KR20080090408A
(ko)
|
2005-11-30 |
2008-10-08 |
아보트 러보러터리즈 |
항-Aβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
|
KR101439828B1
(ko)
|
2005-11-30 |
2014-09-17 |
애브비 인코포레이티드 |
아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
|
US8334257B2
(en)
|
2005-12-20 |
2012-12-18 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
EA017417B1
(ru)
|
2006-02-01 |
2012-12-28 |
Сефалон Астралия Пти Лтд. |
КОНСТРУКТ ОДНОДОМЕННОГО АНТИТЕЛА, КОТОРЫЙ СВЯЗЫВАЕТСЯ С ЧЕЛОВЕЧЕСКИМ TNF-α, И ЕГО ПРИМЕНЕНИЕ
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-22(il-22)之抗體及其用途
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
KR20150064254A
(ko)
*
|
2006-04-05 |
2015-06-10 |
애브비 바이오테크놀로지 리미티드 |
항체 정제
|
US9605064B2
(en)
*
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
US20080118496A1
(en)
*
|
2006-04-10 |
2008-05-22 |
Medich John R |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
EP2012586A4
(en)
|
2006-04-10 |
2010-08-18 |
Abbott Biotech Ltd |
USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS
|
EP2010214A4
(en)
|
2006-04-10 |
2010-06-16 |
Abbott Biotech Ltd |
USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
|
US20090317399A1
(en)
*
|
2006-04-10 |
2009-12-24 |
Pollack Paul F |
Uses and compositions for treatment of CROHN'S disease
|
EP2666472A3
(en)
|
2006-04-10 |
2014-04-02 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of psoriatic arthritis
|
EP2666479A3
(en)
|
2006-04-10 |
2014-03-26 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
US20080131374A1
(en)
*
|
2006-04-19 |
2008-06-05 |
Medich John R |
Uses and compositions for treatment of rheumatoid arthritis
|
US20080311043A1
(en)
*
|
2006-06-08 |
2008-12-18 |
Hoffman Rebecca S |
Uses and compositions for treatment of psoriatic arthritis
|
US20100021451A1
(en)
*
|
2006-06-08 |
2010-01-28 |
Wong Robert L |
Uses and compositions for treatment of ankylosing spondylitis
|
TWI542374B
(zh)
|
2006-06-30 |
2016-07-21 |
艾伯維生物技術有限責任公司 |
自動注射裝置
|
RU2472807C2
(ru)
|
2006-09-08 |
2013-01-20 |
Эбботт Лэборетриз |
Интерлейкин-13-связывающие белки
|
EP2500415A1
(en)
|
2006-09-13 |
2012-09-19 |
Abbott Laboratories |
Cell culture improvements
|
US8911964B2
(en)
|
2006-09-13 |
2014-12-16 |
Abbvie Inc. |
Fed-batch method of making human anti-TNF-alpha antibody
|
MX2009002748A
(es)
|
2006-09-13 |
2009-03-26 |
Abbott Lab |
Mejoras de cultivos celulares.
|
KR20150002896A
(ko)
*
|
2006-10-27 |
2015-01-07 |
애브비 바이오테크놀로지 리미티드 |
결정형 항-hTNF알파 항체
|
EP2099454A4
(en)
|
2006-11-17 |
2010-11-10 |
Abbott Lab |
AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS
|
EP2101780B1
(en)
|
2006-11-21 |
2013-10-09 |
Kalobios Pharmaceuticals, Inc. |
Methods of treating chronic inflammatory diseases using a gm-csf antagonist
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
WO2008082651A2
(en)
|
2006-12-29 |
2008-07-10 |
Abbott Laboratories |
Dual-specific il-1a/ il-1b antibodies
|
WO2008088823A2
(en)
*
|
2007-01-16 |
2008-07-24 |
Abbott Laboratories |
Methods for treating psoriasis
|
JP2008209378A
(ja)
*
|
2007-01-31 |
2008-09-11 |
Fujifilm Corp |
バイオセンサー基板
|
AU2008214359B2
(en)
|
2007-02-05 |
2014-01-16 |
Apellis Pharmaceuticals, Inc. |
Local complement inhibition for treatment of complement-mediated disorders
|
US8895004B2
(en)
|
2007-02-27 |
2014-11-25 |
AbbVie Deutschland GmbH & Co. KG |
Method for the treatment of amyloidoses
|
NZ579594A
(en)
|
2007-03-12 |
2012-03-30 |
Esbatech Alcon Biomed Res Unit |
Sequence based engineering and optimization of single chain antibodies
|
TW200902064A
(en)
*
|
2007-03-28 |
2009-01-16 |
Wyeth Corp |
Methods and compositions for modulating IL-17F/IL-17A biological activity
|
US7807168B2
(en)
*
|
2007-04-10 |
2010-10-05 |
Vaccinex, Inc. |
Selection of human TNFα specific antibodies
|
WO2008124858A2
(en)
*
|
2007-04-11 |
2008-10-23 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. |
Targeted receptor
|
EP2679995A1
(en)
|
2007-05-31 |
2014-01-01 |
AbbVie Inc. |
Biomarkers predictive of the responsiveness to TNF-alfa inhibitors in autoimmune disorders
|
WO2008150490A2
(en)
*
|
2007-06-01 |
2008-12-11 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of psoriasis and crohn's disease
|
MX2009013137A
(es)
*
|
2007-06-06 |
2010-04-30 |
Domantis Ltd |
Metodos para seleccionar polipeptidos resistentes a la proteasa.
|
BRPI0812398A2
(pt)
*
|
2007-06-06 |
2019-09-24 |
Domantis Ltd |
domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão
|
WO2008154543A2
(en)
|
2007-06-11 |
2008-12-18 |
Abbott Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis
|
SI2170390T1
(sl)
|
2007-06-14 |
2019-02-28 |
Biogen Ma Inc. |
Oblike protitelesa natalizumab
|
HUE027507T2
(en)
*
|
2007-06-25 |
2016-10-28 |
Esbatech Alcon Biomed Res Unit |
Procedures for Modifying Antibodies and Modified Antibodies with Improved Functional Properties
|
ES2532725T3
(es)
*
|
2007-06-25 |
2015-03-31 |
Esbatech, An Alcon Biomedical Research Unit Llc |
Modificación por ingeniería genética basada en secuencia y optimización de anticuerpos de cadena sencilla
|
WO2009011782A2
(en)
*
|
2007-07-13 |
2009-01-22 |
Abbott Biotechnology Ltd. |
METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR
|
CN101980722A
(zh)
|
2007-08-08 |
2011-02-23 |
雅培制药有限公司 |
结晶抗体的组合物和方法
|
CA3128656A1
(en)
|
2007-08-22 |
2009-02-26 |
The Regents Of The University Of California |
Activatable binding polypeptides and methods of identification and use thereof
|
MX2010002269A
(es)
*
|
2007-08-28 |
2010-03-25 |
Abbott Biotech Ltd |
Composiciones y metodos que comprenden proteinas de union para adalimumab.
|
RU2499599C2
(ru)
|
2007-09-28 |
2013-11-27 |
Интрексон Корпорейшн |
Конструкции терапевтического переключения генов и биореакторы для экспрессии биотерапевтических молекул и их применение
|
JP2009082033A
(ja)
*
|
2007-09-28 |
2009-04-23 |
Kaneka Corp |
完全ヒト型抗体生産法
|
CA2706700A1
(en)
|
2007-11-08 |
2009-05-14 |
Cytimmune Sciences, Inc. |
Compositions and methods for generating antibodies
|
CN101969971A
(zh)
|
2007-11-30 |
2011-02-09 |
雅培制药有限公司 |
蛋白制剂及其制备方法
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
WO2009086550A1
(en)
*
|
2008-01-03 |
2009-07-09 |
Abbott Laboratories |
Predicting long-term efficacy of a compound in the treatment of psoriasis
|
CA2711984A1
(en)
|
2008-01-15 |
2009-07-23 |
Abbott Gmbh & Co. Kg |
Powdered protein compositions and methods of making same
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
RU2540018C2
(ru)
|
2008-03-13 |
2015-01-27 |
Биотест Аг |
Средство для лечения заболевания
|
EP2265643B1
(en)
|
2008-03-13 |
2016-10-19 |
Biotest AG |
Dosing regimen for treating psoriasis and rheumatoid arthritis
|
WO2009124815A1
(en)
|
2008-03-13 |
2009-10-15 |
Biotest Ag |
Agent for treating disease
|
US8178092B2
(en)
|
2008-03-18 |
2012-05-15 |
Abbott Laboratories |
Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23
|
MX2010011955A
(es)
|
2008-04-29 |
2011-01-21 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
EP2113568A1
(en)
|
2008-04-30 |
2009-11-04 |
Deutsches Rheuma-Forschungszentrum Berlin |
Knock-in mouse for modelling blockade of human TNFalpha
|
AR071698A1
(es)
|
2008-05-09 |
2010-07-07 |
Abbott Gmbh & Co Kg |
Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos
|
WO2009142186A1
(ja)
*
|
2008-05-20 |
2009-11-26 |
株式会社カネカ |
細胞障害性組成物
|
NZ589436A
(en)
|
2008-06-03 |
2012-12-21 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
MX2010013239A
(es)
*
|
2008-06-03 |
2011-02-24 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
KR102095257B1
(ko)
|
2008-06-25 |
2020-04-01 |
노바르티스 아게 |
Vegf를 억제하는 안정하고 가용성인 항체
|
PT3444274T
(pt)
|
2008-06-25 |
2021-03-17 |
Novartis Ag |
Anticorpos que inibem tnf estáveis e solúveis
|
ES2629345T3
(es)
|
2008-06-25 |
2017-08-08 |
Esbatech, An Alcon Biomedical Research Unit Llc |
Optimización de la solubilidad de agentes de unión inmunológica
|
CN105727261A
(zh)
|
2008-06-27 |
2016-07-06 |
杜克大学 |
包含弹性蛋白样肽的治疗剂
|
KR20110044992A
(ko)
*
|
2008-07-02 |
2011-05-03 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
TGF-β 길항제 다중-표적 결합 단백질
|
JP2011527579A
(ja)
|
2008-07-08 |
2011-11-04 |
アボット・ラボラトリーズ |
プロスタグランジンe2結合タンパク質およびこの使用
|
CN102149825B
(zh)
|
2008-07-08 |
2015-07-22 |
Abbvie公司 |
前列腺素e2双重可变结构域免疫球蛋白及其用途
|
EP2337799A2
(en)
*
|
2008-08-28 |
2011-06-29 |
Wyeth LLC |
Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
|
CN102281898B
(zh)
*
|
2008-10-07 |
2015-06-03 |
成功大学 |
Il-20拮抗剂在治疗类风湿性关节炎和骨质疏松症中的应用
|
MX2011004558A
(es)
|
2008-10-29 |
2011-06-01 |
Wyeth Llc |
Procedimientos para la purificacion de moleculas de union a antigeno de un unico dominio.
|
EP2362767B1
(en)
|
2008-10-29 |
2017-12-06 |
Ablynx N.V. |
Formulations of single domain antigen binding molecules
|
US8415291B2
(en)
|
2008-10-31 |
2013-04-09 |
Centocor Ortho Biotech Inc. |
Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
|
CN101419224B
(zh)
*
|
2008-11-06 |
2012-08-22 |
复旦大学附属华山医院 |
一种同时测定人血浆中霉酚酸酯、霉酚酸及其代谢物的方法
|
KR20110096553A
(ko)
*
|
2008-11-28 |
2011-08-30 |
아보트 러보러터리즈 |
안정한 항체 조성물 및 이의 안정화 방법
|
MX2011007030A
(es)
|
2008-12-30 |
2011-07-20 |
Centocor Ortho Biotech Inc |
Marcadores sericos que predicen la respuesta clinica a los anticuerpos anti-factor de necrosis tumoral alfa en pacientes con espondilitis anquilosante.
|
CN101766602B
(zh)
*
|
2008-12-30 |
2012-01-11 |
中国医学科学院血液病医院(血液学研究所) |
取代芳香基腙类化合物在作为肿瘤坏死因子抑制剂药物方面的应用
|
RU2636046C2
(ru)
|
2009-01-12 |
2017-11-17 |
Сайтомкс Терапьютикс, Инк |
Композиции модифицированных антител, способы их получения и применения
|
EP2398494A4
(en)
|
2009-02-23 |
2015-10-28 |
Cytomx Therapeutics Inc |
Proproteins and their methods of use
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
JP5836807B2
(ja)
|
2009-03-05 |
2015-12-24 |
アッヴィ・インコーポレイテッド |
Il−17結合タンパク質
|
US20120135005A1
(en)
*
|
2009-04-16 |
2012-05-31 |
Harding Fiona A |
ANTI-TNF-a ANTIBODIES AND THEIR USES
|
CN101875694B
(zh)
*
|
2009-04-28 |
2014-04-02 |
中国医学科学院基础医学研究所 |
TNFα的抗体及其用途
|
EP2424594A4
(en)
|
2009-04-29 |
2014-12-24 |
Abbvie Biotechnology Ltd |
AUTOMATIC INJECTION DEVICE
|
RU2560701C2
(ru)
*
|
2009-05-04 |
2015-08-20 |
Эббви Байотекнолоджи Лтд. |
Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа
|
WO2010132872A1
(en)
*
|
2009-05-15 |
2010-11-18 |
Novimmune S.A |
Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists
|
TW201109438A
(en)
*
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
PT3311828T
(pt)
|
2009-08-14 |
2021-05-05 |
Phasebio Pharmaceuticals Inc |
Péptidos intestinais vasoativos modificados
|
US20110044981A1
(en)
*
|
2009-08-21 |
2011-02-24 |
Spangler Rhyannon |
Methods and compositions for treatment of pulmonary fibrotic disorders
|
CN102741288B
(zh)
|
2009-08-29 |
2015-08-19 |
Abbvie公司 |
治疗用dll4结合蛋白
|
PE20121530A1
(es)
|
2009-09-01 |
2012-12-22 |
Abbvie Inc |
Inmunoglobulinas con dominio variable dual
|
AU2010291927A1
(en)
*
|
2009-09-14 |
2012-04-12 |
AbbVie Deutschland GmbH & Co. KG |
Methods for treating psoriasis
|
US20110071054A1
(en)
*
|
2009-09-24 |
2011-03-24 |
Xbiotech, Inc. |
Panel of monoclonal antibody containing pharmaceutical compositions
|
CA2772945A1
(en)
|
2009-09-25 |
2011-03-31 |
Xoma Technology Ltd. |
Screening methods
|
JP2013507928A
(ja)
|
2009-10-15 |
2013-03-07 |
アボット・ラボラトリーズ |
二重可変ドメイン免疫グロブリンおよびその使用
|
MX343328B
(es)
*
|
2009-10-26 |
2016-11-01 |
Nestec Sa |
Analisis para la deteccion de farmacos anti-tnf y anticuerpos.
|
UY32979A
(es)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US20110150861A1
(en)
|
2009-10-30 |
2011-06-23 |
Abbott Laboratories |
Sorf constructs and multiple gene expression
|
TW201121568A
(en)
|
2009-10-31 |
2011-07-01 |
Abbott Lab |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
US9244063B2
(en)
|
2009-11-11 |
2016-01-26 |
Gentian As |
Immunoassay for assessing related analytes of different origin
|
GB0920944D0
(en)
|
2009-11-30 |
2010-01-13 |
Biotest Ag |
Agents for treating disease
|
US8871208B2
(en)
*
|
2009-12-04 |
2014-10-28 |
Abbvie Inc. |
11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
|
CN102656190A
(zh)
|
2009-12-08 |
2012-09-05 |
雅培股份有限两合公司 |
用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
|
NZ600069A
(en)
|
2009-12-15 |
2015-02-27 |
Abbvie Biotechnology Ltd |
Improved firing button for automatic injection device
|
US20110150891A1
(en)
*
|
2009-12-16 |
2011-06-23 |
Philip Bosch |
Methods of Treating Interstitial Cystitis
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
WO2011092715A2
(en)
*
|
2010-01-27 |
2011-08-04 |
Tata Memorial Centre |
Method for in-vivo binding of chromatin fragments
|
CA2789168A1
(en)
|
2010-02-02 |
2011-08-11 |
Abbott Biotechnology Ltd. |
Methods and compositions for predicting responsiveness to treatment with tnf-.alpha. inhibitor
|
CN102167741B
(zh)
*
|
2010-02-25 |
2014-05-14 |
上海百迈博制药有限公司 |
一种全人源抗TNF-α单克隆抗体、其制备方法及用途
|
AU2011223919B2
(en)
|
2010-03-02 |
2015-03-19 |
Abbvie Inc. |
Therapeutic DLL4 binding proteins
|
SG184473A1
(en)
|
2010-04-07 |
2012-11-29 |
Abbvie Inc |
Tnf-alpha binding proteins
|
WO2011130377A2
(en)
|
2010-04-15 |
2011-10-20 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
EP3466977B1
(en)
|
2010-04-16 |
2022-01-05 |
Biogen MA Inc. |
Anti-vla-4 antibodies
|
NZ702172A
(en)
|
2010-04-21 |
2016-03-31 |
Abbvie Biotechnology Ltd |
Wearable automatic injection device for controlled delivery of therapeutic agents
|
KR101848225B1
(ko)
|
2010-05-14 |
2018-04-12 |
애브비 인코포레이티드 |
Il-1 결합 단백질
|
WO2011146727A1
(en)
|
2010-05-19 |
2011-11-24 |
Philip Bosch |
Methods of treating interstitial cystitis
|
PT2575884T
(pt)
|
2010-06-03 |
2018-10-31 |
Abbvie Biotechnology Ltd |
Utilizações e composições para o tratamento de hidradenite supurativa (hs)
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
WO2012018790A2
(en)
|
2010-08-03 |
2012-02-09 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
CN103298833B
(zh)
|
2010-08-14 |
2015-12-16 |
Abbvie公司 |
β淀粉样蛋白结合蛋白
|
EP2606067B1
(en)
|
2010-08-19 |
2018-02-21 |
Zoetis Belgium S.A. |
Anti-ngf antibodies and their use
|
CN103260639A
(zh)
|
2010-08-26 |
2013-08-21 |
Abbvie公司 |
双重可变结构域免疫球蛋白及其用途
|
AR083495A1
(es)
|
2010-10-22 |
2013-02-27 |
Esbatech Alcon Biomed Res Unit |
Anticuerpos estables y solubles
|
UA113500C2
(xx)
|
2010-10-29 |
2017-02-10 |
|
Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
|
JP6068352B2
(ja)
|
2010-10-29 |
2017-01-25 |
アッヴィ・インコーポレイテッド |
アポトーシス誘発剤を含む固体分散体
|
BR112013010857A2
(pt)
*
|
2010-11-02 |
2016-09-13 |
Abbott Laboratoires |
imonoglubulinas de duplo domínio variável e usos das mesmas
|
DK2637690T3
(da)
|
2010-11-11 |
2017-01-02 |
Abbvie Biotechnology Ltd |
Flydende ANTI-TNF-alpha-antistofformuleringer med høj koncentration
|
SG190399A1
(en)
|
2010-11-23 |
2013-06-28 |
Abbvie Inc |
Methods of treatment using selective bcl-2 inhibitors
|
BR112013012740A2
(pt)
|
2010-11-23 |
2016-09-13 |
Abbvie Inc |
sais e formas cristalinas de um agente que induz apoptose
|
AR084210A1
(es)
*
|
2010-12-08 |
2013-05-02 |
Abbott Lab |
PROTEINAS DE UNION AL TNF-a
|
US20120275996A1
(en)
|
2010-12-21 |
2012-11-01 |
Abbott Laboratories |
IL-1 Binding Proteins
|
AU2011361720B2
(en)
|
2010-12-21 |
2017-04-27 |
Abbvie Inc. |
IL-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
|
EP2490024A1
(en)
|
2010-12-22 |
2012-08-22 |
Proteomika, S.L. |
Method to optimize the treatment of patients with biological drugs
|
JP6478214B2
(ja)
|
2011-01-24 |
2019-03-06 |
アッヴィ バイオテクノロジー リミテッド |
オーバーモールド把持面を有する自動注射器
|
CA2824454C
(en)
|
2011-01-24 |
2018-10-23 |
Abbvie Biotechnology Ltd. |
Removal of needle shields from syringes and automatic injection devices
|
AU2012210170B2
(en)
|
2011-01-24 |
2016-09-29 |
Elcam Medical Agricultural Cooperative Association Ltd. |
Injector
|
RU2455025C1
(ru)
*
|
2011-02-10 |
2012-07-10 |
Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") |
Способ фармакологической коррекции ишемии конечности смесью растворов гомеопатических разведений
|
JP2014508715A
(ja)
|
2011-03-07 |
2014-04-10 |
国立大学法人徳島大学 |
筋萎縮性側索硬化症の治療方法
|
US20120233834A1
(en)
|
2011-03-18 |
2012-09-20 |
Abbott Biotechnology Ltd. |
Systems, devices and methods for assembling automatic injection devices and sub-assemblies thereof
|
TWI588156B
(zh)
|
2011-03-28 |
2017-06-21 |
賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
MX2013011263A
(es)
|
2011-03-29 |
2014-03-27 |
Abbvie Inc |
Despliegue de cubierta mejorado en dispositivos de inyeccion automaticos.
|
EP4299093A3
(en)
|
2011-04-21 |
2024-03-13 |
AbbVie Inc. |
Wearable automatic injection device for controlled administration of therapeutic agents
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
AU2012258637B2
(en)
|
2011-05-24 |
2017-07-20 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
SI3575792T1
(sl)
|
2011-05-31 |
2023-04-28 |
Biogen Ma Inc. |
Metoda ocenjevanja tveganja progresivne multifokalne levkoencefalopatije
|
WO2012170524A1
(en)
|
2011-06-06 |
2012-12-13 |
Phasebio Pharmaceuticals, Inc. |
Use of modified vasoactive intestinal peptides in the treatment of hypertension
|
CA2841970A1
(en)
|
2011-07-13 |
2013-01-17 |
Abbvie Inc. |
Methods and compositions for treating asthma using anti-il-13 antibodies
|
GB201112429D0
(en)
*
|
2011-07-19 |
2011-08-31 |
Glaxo Group Ltd |
Antigen-binding proteins with increased FcRn binding
|
BR112014002133A2
(pt)
*
|
2011-08-01 |
2017-02-21 |
Avaxia Biologics Inc |
anticorpo policlonal bovino específico para tnf humano
|
TWI577696B
(zh)
*
|
2011-10-20 |
2017-04-11 |
Esba科技 諾華有限責任公司 |
穩定的多重抗原結合抗體
|
RU2014120981A
(ru)
|
2011-10-24 |
2015-12-10 |
Эббви Инк. |
Иммунные связывающие агенты против склеростина
|
IN2014CN03936A
(sk)
|
2011-10-24 |
2015-09-04 |
Abbvie Inc |
|
EP2771361A1
(en)
|
2011-10-24 |
2014-09-03 |
AbbVie Inc. |
Bispecific immunobinders directed against tnf and il-17
|
US20140017174A1
(en)
|
2011-11-30 |
2014-01-16 |
Raja Atreya |
Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
|
US10118958B2
(en)
|
2011-12-14 |
2018-11-06 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
JP6336397B2
(ja)
|
2011-12-14 |
2018-06-06 |
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー |
鉄関連障害を診断および治療するための組成物および方法
|
WO2013087912A1
(en)
|
2011-12-16 |
2013-06-20 |
Synthon Biopharmaceuticals B.V. |
Compounds and methods for treating inflammatory diseases
|
UY34556A
(es)
|
2011-12-30 |
2013-07-31 |
Abbvie Inc |
Dominio variable dual de inmunoglobulinas y sus usos
|
BR112014015851A2
(pt)
|
2011-12-30 |
2019-09-24 |
Abbvie Inc |
proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
|
JP6271441B2
(ja)
|
2012-01-27 |
2018-01-31 |
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー |
神経突起変性に関連する疾患を診断および治療するための組成物および方法
|
JP2015509526A
(ja)
|
2012-03-07 |
2015-03-30 |
カディラ ヘルスケア リミティド |
医薬製剤
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
EP2657334B1
(en)
|
2012-04-26 |
2016-07-06 |
GeneFrontier Corporation |
Efficient method for displaying protein multimer
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
CA2875783C
(en)
|
2012-06-06 |
2018-12-11 |
Zoetis Llc |
Caninized anti-ngf antibodies and methods thereof
|
EP2859017B1
(en)
|
2012-06-08 |
2019-02-20 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
US9670276B2
(en)
|
2012-07-12 |
2017-06-06 |
Abbvie Inc. |
IL-1 binding proteins
|
SG11201501464TA
(en)
|
2012-08-31 |
2015-03-30 |
Sutro Biopharma Inc |
Modified amino acids comprising an azido group
|
CA2883272A1
(en)
|
2012-09-02 |
2014-03-06 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
HUE049282T2
(hu)
|
2012-09-07 |
2020-09-28 |
Coherus Biosciences Inc |
Adalimumab stabil vizes formulációi
|
SI2897978T1
(sl)
*
|
2012-09-19 |
2017-05-31 |
Abbvie Biotherapeutics Inc. |
Postopki za identifikacijo protiteles z zmanjšano imunogenostjo
|
KR20210111353A
(ko)
|
2012-11-01 |
2021-09-10 |
애브비 인코포레이티드 |
항-vegf/dll4 이원 가변 도메인 면역글로불린 및 이의 용도
|
AU2013337644A1
(en)
|
2012-11-01 |
2015-05-07 |
Abbvie Inc. |
Stable Dual Variable Domain Immunoglobulin protein formulations
|
TWI745610B
(zh)
|
2012-11-14 |
2021-11-11 |
美商再生元醫藥公司 |
重組細胞表面捕捉蛋白質
|
US9550986B2
(en)
|
2012-12-21 |
2017-01-24 |
Abbvie Inc. |
High-throughput antibody humanization
|
US9856319B2
(en)
|
2012-12-28 |
2018-01-02 |
Abbvie Inc. |
Monovalent binding proteins
|
EP2938634A2
(en)
|
2012-12-28 |
2015-11-04 |
AbbVie Inc. |
Dual specific binding proteins having a receptor sequence
|
EP2948178A4
(en)
|
2013-01-25 |
2016-07-20 |
Thymon Llc |
COMPOSITIONS FOR THE SELECTIVE REDUCTION OF CIRCULATING BIOACTIVE SOLUBLE TNF AND METHODS OF TREATING A TNF MEDIATION DISEASE
|
EP2956480B1
(en)
|
2013-02-13 |
2019-09-04 |
Laboratoire Français du Fractionnement et des Biotechnologies |
Highly galactosylated anti-tnf-alpha antibodies and uses thereof
|
EP2830651A4
(en)
|
2013-03-12 |
2015-09-02 |
Abbvie Inc |
HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
|
US9194873B2
(en)
|
2013-03-14 |
2015-11-24 |
Abbott Laboratories |
HCV antigen-antibody combination assay and methods and compositions for use therein
|
WO2014159579A1
(en)
*
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
US20140275082A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
JP2016512241A
(ja)
|
2013-03-14 |
2016-04-25 |
アボット・ラボラトリーズAbbott Laboratories |
改良された抗体検出のためのhcvns3組換え抗原およびこの突然変異体
|
WO2014158231A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
Low acidic species compositions and methods for producing and using the same
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
AU2014240431A1
(en)
|
2013-03-14 |
2015-08-27 |
Abbvie Inc. |
Low acidic species compositions and methods for producing the same using displacement chromatography
|
CN113549148A
(zh)
|
2013-03-14 |
2021-10-26 |
雅培制药有限公司 |
Hcv核心脂质结合结构域单克隆抗体
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
EP2968541A4
(en)
|
2013-03-15 |
2017-02-08 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
AU2014227664A1
(en)
|
2013-03-15 |
2015-09-24 |
Abbvie Inc. |
Dual specific binding proteins directed against TNFalpha
|
MX2015013166A
(es)
|
2013-03-15 |
2015-12-11 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
|
KR101671955B1
(ko)
*
|
2013-05-22 |
2016-11-07 |
메타볼랩(주) |
항 TNF-α/CXCL10 이중 타겟 항체 및 그의 용도
|
JP6581572B2
(ja)
|
2013-06-07 |
2019-09-25 |
デューク ユニバーシティ |
補体因子h阻害薬
|
WO2015006555A2
(en)
|
2013-07-10 |
2015-01-15 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
WO2015017683A1
(en)
*
|
2013-07-31 |
2015-02-05 |
Malast Mary |
Antimicrobial compositions and methods of use
|
JP6546178B2
(ja)
|
2013-09-13 |
2019-07-17 |
ジェネンテック, インコーポレイテッド |
細胞株中の宿主細胞タンパク質及び組換えポリペプチド産物を検出及び定量化するための組成物並びに方法
|
KR102373930B1
(ko)
|
2013-09-13 |
2022-03-11 |
제넨테크, 인크. |
정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물
|
US9598667B2
(en)
|
2013-10-04 |
2017-03-21 |
Abbvie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
CA2926644A1
(en)
|
2013-10-06 |
2015-04-09 |
Abbvie Inc. |
Dual specific binding proteins directed against immune cell receptors and autoantigens
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
WO2015057910A1
(en)
|
2013-10-16 |
2015-04-23 |
Oncobiologics, Inc. |
Buffer formulations for enhanced antibody stability
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
JP2016540761A
(ja)
|
2013-12-02 |
2016-12-28 |
アッヴィ・インコーポレイテッド |
変形性関節症を治療するための組成物及び方法
|
CN103965357B
(zh)
|
2013-12-31 |
2016-08-17 |
嘉和生物药业有限公司 |
一种抗人rankl抗体
|
EP3110976B1
(en)
|
2014-02-27 |
2020-05-13 |
Biogen MA Inc. |
Method of assessing risk of pml
|
EP3116891B1
(en)
|
2014-03-10 |
2020-02-12 |
Richter Gedeon Nyrt. |
Immunoglobulin purification using pre-cleaning steps
|
IL295906A
(en)
|
2014-03-21 |
2022-10-01 |
Abbvie Inc |
Antibodies against egfr and drug antibody conjugates
|
AR099625A1
(es)
|
2014-03-21 |
2016-08-03 |
Lilly Co Eli |
Anticuerpos de il-21
|
WO2015151115A1
(en)
*
|
2014-04-02 |
2015-10-08 |
Intas Pharmaceuticals Limited |
Liquid pharmaceutical composition of adalimumab
|
CA2947982C
(en)
|
2014-05-08 |
2022-11-29 |
Phasebio Pharmaceuticals, Inc. |
Methods and compositions for treating cystic fibrosis
|
ES2607489T3
(es)
|
2014-05-23 |
2017-03-31 |
Ares Trading S.A. |
Composición farmacéutica líquida
|
HUE029849T2
(en)
|
2014-05-23 |
2017-04-28 |
Ares Trading Sa |
Liquid pharmaceutical composition
|
EP2946766B1
(en)
|
2014-05-23 |
2016-03-02 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
FR3022462B1
(fr)
*
|
2014-06-18 |
2018-04-27 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Composition orale d'anticorps anti-tnfalpha
|
US20170183376A1
(en)
|
2014-06-24 |
2017-06-29 |
Insight Biopharmaceuticals Ltd. |
Methods of purifying antibodies
|
US10183994B2
(en)
*
|
2014-06-30 |
2019-01-22 |
Merck Patent Gmbh |
Anti-TNFα antibodies with pH-dependent antigen binding for improved target clearence
|
WO2016004197A1
(en)
|
2014-07-03 |
2016-01-07 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
|
WO2016007764A1
(en)
|
2014-07-09 |
2016-01-14 |
Abbvie Inc. |
Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
|
EP4379725A2
(en)
|
2014-07-11 |
2024-06-05 |
Iogenetics, LLC. |
Immune recognition motifs
|
TWI711629B
(zh)
*
|
2014-09-03 |
2020-12-01 |
德商包林格因蓋爾漢國際股份有限公司 |
靶向IL-23A與TNF-α之化合物及其用途
|
US10435464B1
(en)
|
2014-09-05 |
2019-10-08 |
Coherus Biosciences, Inc. |
Methods for making recombinant proteins
|
HUP1400510A1
(hu)
|
2014-10-28 |
2016-05-30 |
Richter Gedeon Nyrt |
Gyógyászati TNFalfa ellenes antitest készítmény
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
EP3237000A1
(en)
|
2014-12-23 |
2017-11-01 |
Pfizer Inc |
Stable aqueous antibody formulation for anti tnf alpha antibodies
|
EP3085709B1
(en)
|
2014-12-28 |
2019-08-21 |
Genor Biopharma Co., Ltd |
Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
|
WO2016118707A1
(en)
|
2015-01-21 |
2016-07-28 |
Oncobiologics, Inc. |
Modulation of charge variants in a monoclonal antibody composition
|
EP3053572A1
(en)
|
2015-02-06 |
2016-08-10 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
CN114652817A
(zh)
|
2015-02-09 |
2022-06-24 |
费斯生物制药公司 |
用于治疗肌肉疾病和病症的方法和组合物
|
CN105777905B
(zh)
*
|
2015-03-24 |
2019-06-25 |
广东东阳光药业有限公司 |
一种全人源抗TNF-α单克隆抗体及其应用
|
EP3078675A1
(en)
|
2015-04-10 |
2016-10-12 |
Ares Trading S.A. |
Induction dosing regimen for the treatment of tnf alpha mediated disorders
|
WO2016179469A1
(en)
*
|
2015-05-07 |
2016-11-10 |
Abbvie Inc. |
Methods and compositions for diagnosing and treating inflammatory bowel disease
|
KR102661078B1
(ko)
|
2015-05-29 |
2024-05-23 |
애브비 인코포레이티드 |
항-cd40 항체 및 그의 용도
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
HU231463B1
(hu)
|
2015-08-04 |
2024-01-28 |
Richter Gedeon Nyrt. |
Módszer rekombináns proteinek galaktóz tartalmának növelésére
|
US11583584B1
(en)
|
2015-10-28 |
2023-02-21 |
Coherus Biosciences, Inc. |
Stable protein compositions and methods of their use
|
US11229702B1
(en)
|
2015-10-28 |
2022-01-25 |
Coherus Biosciences, Inc. |
High concentration formulations of adalimumab
|
GB201522394D0
(en)
|
2015-12-18 |
2016-02-03 |
Ucb Biopharma Sprl |
Antibodies
|
WO2017136433A1
(en)
|
2016-02-03 |
2017-08-10 |
Oncobiologics, Inc. |
Buffer formulations for enhanced antibody stability
|
US10465003B2
(en)
|
2016-02-05 |
2019-11-05 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
|
SG11201808041UA
(en)
*
|
2016-03-17 |
2018-10-30 |
Numab Innovation Ag |
ANTI-TNFa-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
|
RS61374B1
(sr)
*
|
2016-03-17 |
2021-02-26 |
Tillotts Pharma Ag |
Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti
|
JP2019513737A
(ja)
|
2016-04-08 |
2019-05-30 |
ギリアード サイエンシーズ, インコーポレイテッド |
がん、炎症性疾患および自己免疫疾患を処置するための組成物および方法
|
US11071782B2
(en)
|
2016-04-20 |
2021-07-27 |
Coherus Biosciences, Inc. |
Method of filling a container with no headspace
|
LT3448391T
(lt)
|
2016-04-27 |
2024-06-25 |
AbbVie Manufacturing Management Unlimited Company |
Ligų, kurių atveju il-13 aktyvumas yra žalingas, gydymo būdas, panaudojant anti-il-13 antikūnus
|
KR20220119529A
(ko)
|
2016-06-02 |
2022-08-29 |
애브비 인코포레이티드 |
글루코코르티코이드 수용체 작용제 및 이의 면역접합체
|
TWI762487B
(zh)
|
2016-06-08 |
2022-05-01 |
美商艾伯維有限公司 |
抗-b7-h3抗體及抗體藥物結合物
|
US20190153108A1
(en)
|
2016-06-08 |
2019-05-23 |
Abbvie Inc. |
Anti-egfr antibody drug conjugates
|
JP2019521114A
(ja)
|
2016-06-08 |
2019-07-25 |
アッヴィ・インコーポレイテッド |
抗egfr抗体薬物コンジュゲート
|
CA3027033A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
CA3027044A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
CN109641962A
(zh)
|
2016-06-08 |
2019-04-16 |
艾伯维公司 |
抗b7-h3抗体和抗体药物偶联物
|
WO2017218698A1
(en)
|
2016-06-15 |
2017-12-21 |
Sutro Biopharma, Inc. |
Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
|
WO2018018613A1
(zh)
|
2016-07-29 |
2018-02-01 |
广东东阳光药业有限公司 |
一种提高抗体纯度的细胞培养基和培养方法
|
US10751324B2
(en)
|
2016-09-02 |
2020-08-25 |
The University Of Chicago |
Treatment of TNF- alpha cytotoxicity
|
EP3512875A2
(en)
*
|
2016-09-15 |
2019-07-24 |
Quadrucept Bio Limited |
Multimers, tetramers&octamers
|
EP3519825A1
(en)
|
2016-10-03 |
2019-08-07 |
Abbott Laboratories |
Improved methods of assessing gfap status in patient samples
|
WO2018075408A1
(en)
|
2016-10-17 |
2018-04-26 |
Alexion Pharmaceuticals, Inc. |
Methods of treating acute myeloid leukemia (aml) with combinations of anti-cd200 antibodies, cytarabine, and daunorubicin
|
MX2019004580A
(es)
|
2016-10-21 |
2019-08-12 |
Amgen Inc |
Formulaciones farmaceuticas y metodos para prepararlas.
|
WO2018102594A1
(en)
|
2016-12-01 |
2018-06-07 |
Alexion Pharmaceuticals, Inc. |
Methods of treating solid tumors with anti-cd200 antibodies
|
US20180193003A1
(en)
|
2016-12-07 |
2018-07-12 |
Progenity Inc. |
Gastrointestinal tract detection methods, devices and systems
|
EP3554342A1
(en)
|
2016-12-14 |
2019-10-23 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
WO2018112334A1
(en)
*
|
2016-12-16 |
2018-06-21 |
Bluefin Biomedicine, Inc. |
Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof
|
JOP20190162A1
(ar)
|
2016-12-30 |
2019-06-27 |
Biocad Joint Stock Co |
تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
|
CA3049857A1
(en)
|
2017-01-11 |
2018-07-19 |
Celltrion Inc. |
Stable liquid formulation
|
TWI787230B
(zh)
|
2017-01-20 |
2022-12-21 |
法商賽諾菲公司 |
抗TGF-β抗體及其用途
|
AR110755A1
(es)
|
2017-01-20 |
2019-05-02 |
Genzyme Corp |
Anticuerpos dirigidos a hueso
|
MX2019008989A
(es)
|
2017-01-30 |
2019-10-09 |
Janssen Biotech Inc |
Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la artritis psoriasica activa.
|
AU2017398101A1
(en)
|
2017-02-07 |
2019-08-01 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
|
US11608357B2
(en)
|
2018-08-28 |
2023-03-21 |
Arecor Limited |
Stabilized antibody protein solutions
|
EP3372241A1
(en)
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
EP3372242A1
(en)
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
WO2018175942A1
(en)
|
2017-03-23 |
2018-09-27 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
|
WO2018178973A1
(en)
|
2017-03-26 |
2018-10-04 |
Mapi Pharma Ltd. |
Glatiramer depot systems for treating progressive forms of multiple sclerosis
|
WO2018184692A1
(en)
|
2017-04-07 |
2018-10-11 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
CN110546513A
(zh)
|
2017-04-15 |
2019-12-06 |
雅培实验室 |
使用早期生物标记物帮助超急性诊断和确定人类受试者中的创伤性脑损伤的方法
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
CN110651190A
(zh)
|
2017-05-25 |
2020-01-03 |
雅培实验室 |
用早期生物标记物帮助确定是否对已遭受或可能已遭受头部损伤的人受试者执行成像的方法
|
CN110720041B
(zh)
|
2017-05-30 |
2024-04-26 |
雅培实验室 |
用心肌肌钙蛋白i和早期生物标记物帮助诊断和评价人受试者中轻度创伤性脑损伤的方法
|
EP3649474A1
(en)
|
2017-07-03 |
2020-05-13 |
Abbott Laboratories |
Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
|
WO2019067499A1
(en)
|
2017-09-27 |
2019-04-04 |
Alexion Pharmaceuticals, Inc. |
BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
|
ES2877659T3
(es)
|
2017-12-01 |
2021-11-17 |
Abbvie Inc |
Agonista del receptor de glucocorticoides y sus inmunoconjugados
|
CN109879962B
(zh)
*
|
2017-12-06 |
2022-10-11 |
北京科立思维生物科技有限公司 |
抗tnf单链抗体、抗il-6单链抗体及其融合蛋白及其应用
|
JP7379165B2
(ja)
|
2017-12-09 |
2023-11-14 |
アボット・ラボラトリーズ |
Gfapとuch-l1との組合せを使用する、ヒト対象における外傷性脳損傷を診断及び査定する一助となるための方法
|
JP7344801B2
(ja)
|
2017-12-09 |
2023-09-14 |
アボット・ラボラトリーズ |
グリア原線維性酸性タンパク質(gfap)及び/又はユビキチンカルボキシ末端ヒドロラーゼl1(uch-l1)を使用する、整形外科損傷を負っており、軽度外傷性脳損傷(tbi)などの頭部への損傷を負ったか又は負った可能性がある対象についての診断及び査定の一助となるための方法
|
WO2019126536A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals Inc. |
Humanized anti-cd200 antibodies and uses thereof
|
WO2019126133A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals, Inc. |
Liquid formulations of anti-cd200 antibodies
|
CA3093772C
(en)
|
2018-03-12 |
2024-04-16 |
Zoetis Services Llc |
Anti-ngf antibodies and methods thereof
|
US11913951B2
(en)
|
2018-03-26 |
2024-02-27 |
Alexion Pharmaceuticals, Inc. |
High throughput method for measuring the protease activity of complement C3 convertase
|
US20210238289A1
(en)
|
2018-06-04 |
2021-08-05 |
Biogen Ma Inc. |
Anti-vla-4 antibodies having reduced effector function
|
EP3810095A1
(en)
|
2018-06-20 |
2021-04-28 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
JP2021529780A
(ja)
|
2018-07-03 |
2021-11-04 |
ノバルティス アーゲー |
Nlrp3アンタゴニストを使用するtnf阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法
|
CN113329769A
(zh)
|
2018-10-11 |
2021-08-31 |
斯克里普斯研究学院 |
具有反应性精氨酸的抗体化合物及相关的抗体药物缀合物
|
WO2020086728A1
(en)
|
2018-10-24 |
2020-04-30 |
Novartis Inflammasome Research, Inc. |
Compounds and compositions for treating conditions associated with nlrp activity
|
EP3878870A4
(en)
*
|
2018-11-05 |
2022-08-03 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
ANTI-TNFA/ANTI-IL-17A NATURAL ANTIBODY STRUCTURE-LIKE HETERODIMER FORM OF A BISPECIFIC ANTIBODY AND METHODS FOR ITS PRODUCTION
|
HUP1800376A2
(hu)
|
2018-11-07 |
2020-05-28 |
Richter Gedeon Nyrt |
Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer
|
JP2022506891A
(ja)
|
2018-11-13 |
2022-01-17 |
ノバルティス アーゲー |
Nlrp活性に関連する状態を処置するための化合物及び組成物
|
CN113166081A
(zh)
|
2018-11-13 |
2021-07-23 |
诺华股份有限公司 |
用于治疗与nlrp活性相关的病症的化合物和组合物
|
US20220249814A1
(en)
|
2018-11-19 |
2022-08-11 |
Progenity, Inc. |
Methods and devices for treating a disease with biotherapeutics
|
US20220098310A1
(en)
|
2018-12-06 |
2022-03-31 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
CA3124730A1
(en)
|
2018-12-25 |
2020-07-02 |
Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences |
Small rna medicament for prevention and treatment of inflammation-related diseases and combinations thereof
|
JP2022533287A
(ja)
|
2019-01-22 |
2022-07-22 |
ノバルティス アーゲー |
Nlrp活性に関連する状態を処置するための化合物及び組成物
|
HU231498B1
(hu)
|
2019-04-04 |
2024-05-28 |
Richter Gedeon Nyrt |
Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelőző flokkulálás alkalmazásával
|
KR102323342B1
(ko)
*
|
2019-04-26 |
2021-11-08 |
주식회사 와이바이오로직스 |
IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
|
BR112021023295A2
(pt)
|
2019-05-23 |
2022-02-08 |
Janssen Biotech Inc |
Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
|
WO2021002887A1
(en)
|
2019-07-02 |
2021-01-07 |
Novartis Inflammasome Research, Inc. |
Gut-targeted nlrp3 antagonists and their use in therapy
|
CA3143478A1
(en)
*
|
2019-07-09 |
2021-01-14 |
Tomer Hertz |
Antibodies with reduced immunogenicity
|
EP3870261B1
(en)
|
2019-12-13 |
2024-01-31 |
Biora Therapeutics, Inc. |
Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
|
FR3104582A1
(fr)
|
2019-12-17 |
2021-06-18 |
Commissariat A L'energie Atomique Et Aux Energies Alternatives |
Variants de l’adalimumab au potentiel immunogène réduit
|
EP4100435A1
(en)
|
2020-02-05 |
2022-12-14 |
Larimar Therapeutics, Inc. |
Tat peptide binding proteins and uses thereof
|
WO2021178597A1
(en)
|
2020-03-03 |
2021-09-10 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
CA3175523A1
(en)
|
2020-04-13 |
2021-10-21 |
Antti Virtanen |
Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
|
KR20230042301A
(ko)
|
2020-08-04 |
2023-03-28 |
애벗트 라보라토리이즈 |
샘플에서 sars-cov-2 단백질을 검출하기 위한 개선된 방법 및 키트
|
CN111944052B
(zh)
*
|
2020-08-26 |
2022-02-11 |
中国药科大学 |
抗TNF-α/PD-1双特异性抗体及其应用
|
CN112010970B
(zh)
*
|
2020-10-30 |
2021-01-12 |
迈威(上海)生物科技股份有限公司 |
一种去除重组表达抗体聚体和降解产物的方法
|
US20220170948A1
(en)
|
2020-12-01 |
2022-06-02 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
US11672929B2
(en)
|
2020-12-02 |
2023-06-13 |
Breathe Restore, Inc. |
Product delivery devices and methods
|
JP2023554200A
(ja)
|
2020-12-09 |
2023-12-26 |
エイチケー イノ.エヌ コーポレーション |
抗OX40L抗体、抗OX40L及び抗TNFαの二重特異性抗体、並びにこれらの用途
|
AU2021401815A1
(en)
*
|
2020-12-18 |
2023-07-06 |
Elanco Us Inc. |
Tnf alpha and ngf antibodies for veterinary use
|
WO2022147147A1
(en)
|
2020-12-30 |
2022-07-07 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
UY39610A
(es)
|
2021-01-20 |
2022-08-31 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
CA3207134A1
(en)
*
|
2021-02-19 |
2022-08-25 |
Jeffrey A. Ledbetter |
Dnase fusion polypeptides and related compositions and methods
|
CA3216585A1
(en)
|
2021-04-27 |
2022-11-03 |
Nathaniel SILVER |
Non-viral dna vectors expressing therapeutic antibodies and uses thereof
|
WO2022232286A1
(en)
|
2021-04-27 |
2022-11-03 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
US20220381796A1
(en)
|
2021-05-18 |
2022-12-01 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
US20240118279A1
(en)
|
2021-06-14 |
2024-04-11 |
Abbott Laboratories |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
US20240210419A1
(en)
*
|
2021-06-22 |
2024-06-27 |
University Of Virginia Patent Foundation |
Compositions and methods for detecting and regulating fibronectin-integrin interactions and signaling
|
CN117500816A
(zh)
|
2021-08-26 |
2024-02-02 |
映恩生物制药(苏州)有限公司 |
一种甾体化合物及其缀合物
|
AU2022339759A1
(en)
|
2021-08-31 |
2024-03-07 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
AU2022354059A1
(en)
|
2021-09-30 |
2024-03-28 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
CA3240822A1
(en)
|
2021-12-17 |
2023-06-22 |
Tony Lee |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
WO2023129942A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2023177655A1
(en)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
WO2024006681A1
(en)
*
|
2022-06-28 |
2024-01-04 |
Adafre Biosciences, Llc |
Anti-tnf-αlpha antibodies and compositions
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
CN116903738A
(zh)
*
|
2022-08-02 |
2023-10-20 |
北京绿竹生物技术股份有限公司 |
一种低甘露糖型抗人肿瘤坏死因子-α单抗及其用途
|
WO2024054934A1
(en)
|
2022-09-07 |
2024-03-14 |
Mdx Management Llc |
Shp-1 inhibitors for treating cancer
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|
WO2024097804A1
(en)
|
2022-11-02 |
2024-05-10 |
Mdx Management Llc |
Combination of a tyrosine kinase inhibitor and a pro-inflammatory agent for treating cancer
|